Home Cart Sign in  
Chemical Structure| 442201-24-3 Chemical Structure| 442201-24-3

Structure of Remogliflozin etabonate
CAS No.: 442201-24-3

Chemical Structure| 442201-24-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Remogliflozin etabonate (GSK189075) is an orally active, selective, and low-affinity inhibitor of sodium-glucose cotransporter (SGLT2) with Ki values of 1.95 μM, 43.1 μM, 2.14 μM, and 8.57 μM for hSGLT2, rSGLT2, hSGLT1, and rSGLT1, respectively.

Synonyms: GSK189075

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Remogliflozin etabonate

CAS No. :442201-24-3
Formula : C26H38N2O9
M.W : 522.59
SMILES Code : O=C(OCC)OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=NN(C(C)C)C(C)=C2CC3=CC=C(OC(C)C)C=C3)O1
Synonyms :
GSK189075
MDL No. :MFCD17167013

Safety of Remogliflozin etabonate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

Description
Remogliflozin etabonate (GSK189075) is an orally active, selective, and low-affinity sodium glucose cotransporter (SGLT2) inhibitor, with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, and 8.57 μM for hSGLT2, rSGLT2, hSGLT1, and rSGLT1, respectively. It is a prodrug based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, within the body. This compound demonstrates antidiabetic efficacy in rodent models[1].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00501462 Type 2 Diabetes Mellitus|Diabe... More >>tes Mellitus, Type 2|Renal Insufficiency Less << PHASE1 COMPLETED 2025-03-08 GSK Investigational Site, Orla... More >>ndo, Florida, 32809, United States|GSK Investigational Site, Minneapolis, Minnesota, 55404, United States|GSK Investigational Site, Knoxville, Tennessee, 37920, United States|GSK Investigational Site, Austin, Texas, 78752, United States Less <<
NCT00532610 Type 2 Diabetes Mellitus|Diabe... More >>tes Mellitus, Type 2 Less << PHASE1 COMPLETED 2025-02-08 GSK Investigational Site, Madi... More >>son, Wisconsin, 53704, United States Less <<
NCT00501930 Type 2 Diabetes Mellitus|Diabe... More >>tes Mellitus, Type 2 Less << PHASE1 COMPLETED - GSK Investigational Site, Madi... More >>son, Wisconsin, 53704, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.91mL

0.38mL

0.19mL

9.57mL

1.91mL

0.96mL

19.14mL

3.83mL

1.91mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories